165 related articles for article (PubMed ID: 12637154)
21. System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties.
Kaushansky A; Gordus A; Budnik BA; Lane WS; Rush J; MacBeath G
Chem Biol; 2008 Aug; 15(8):808-17. PubMed ID: 18721752
[TBL] [Abstract][Full Text] [Related]
22. Expression of the ErbB4 receptor causes reversal regulation of PP2A in the Shc signal transduction pathway in human cancer cells.
Yumoto N; Yu X; Hatakeyama M
Mol Cell Biochem; 2006 Apr; 285(1-2):165-71. PubMed ID: 16477370
[TBL] [Abstract][Full Text] [Related]
23. Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype.
Telesco SE; Vadigepalli R; Radhakrishnan R
Biotechnol J; 2013 Dec; 8(12):1452-64. PubMed ID: 24318637
[TBL] [Abstract][Full Text] [Related]
24. Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.
Tvorogov D; Sundvall M; Kurppa K; Hollmén M; Repo S; Johnson MS; Elenius K
J Biol Chem; 2009 Feb; 284(9):5582-91. PubMed ID: 19098003
[TBL] [Abstract][Full Text] [Related]
25. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
26. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
27. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
28. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation.
Shi F; Telesco SE; Liu Y; Radhakrishnan R; Lemmon MA
Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7692-7. PubMed ID: 20351256
[TBL] [Abstract][Full Text] [Related]
29. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.
Plowman GD; Culouscou JM; Whitney GS; Green JM; Carlton GW; Foy L; Neubauer MG; Shoyab M
Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1746-50. PubMed ID: 8383326
[TBL] [Abstract][Full Text] [Related]
30. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development.
Kiguchi K; Bol D; Carbajal S; Beltrán L; Moats S; Chan K; Jorcano J; DiGiovanni J
Oncogene; 2000 Aug; 19(37):4243-54. PubMed ID: 10980598
[TBL] [Abstract][Full Text] [Related]
31. Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology.
Pellat A; Vaquero J; Fouassier L
Hepatology; 2018 Feb; 67(2):762-773. PubMed ID: 28671339
[TBL] [Abstract][Full Text] [Related]
32. Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF-7 breast carcinoma cells.
Egeblad M; Jäättelä M
Int J Cancer; 2000 Jun; 86(5):617-25. PubMed ID: 10797281
[TBL] [Abstract][Full Text] [Related]
33. Peptides for Dual Targeting of ErbB1 and ErbB2: Blocking EGFR Cell Signaling Transduction Pathways for Cancer Chemotherapy.
Patnaik SK; Swaroop AK; Nagarjuna P; Nanjan MJ; Chandrasekar MJN
Curr Mol Pharmacol; 2024; 17(1):e240223214012. PubMed ID: 36843255
[TBL] [Abstract][Full Text] [Related]
34. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
[TBL] [Abstract][Full Text] [Related]
35. ErbB4 promotes cyclooxygenase-2 expression and cell survival in colon epithelial cells.
Frey MR; Hilliard VC; Mullane MT; Polk DB
Lab Invest; 2010 Oct; 90(10):1415-24. PubMed ID: 20585313
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
Qiu C; Tarrant MK; Choi SH; Sathyamurthy A; Bose R; Banjade S; Pal A; Bornmann WG; Lemmon MA; Cole PA; Leahy DJ
Structure; 2008 Mar; 16(3):460-7. PubMed ID: 18334220
[TBL] [Abstract][Full Text] [Related]
37. A tyrosine kinase profile of prostate carcinoma.
Robinson D; He F; Pretlow T; Kung HJ
Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5958-62. PubMed ID: 8650201
[TBL] [Abstract][Full Text] [Related]
38. Stretch-induced fetal type II cell differentiation is mediated via ErbB1-ErbB4 interactions.
Huang Z; Wang Y; Nayak PS; Dammann CE; Sanchez-Esteban J
J Biol Chem; 2012 May; 287(22):18091-102. PubMed ID: 22493501
[TBL] [Abstract][Full Text] [Related]
39. Reversion of human prostate tumorigenic growth by azatyrosine.
Benoit RM; Eiseman J; Jacobs SC; Kyprianou N
Urology; 1995 Sep; 46(3):370-7. PubMed ID: 7660512
[TBL] [Abstract][Full Text] [Related]
40. ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition.
Muraoka-Cook RS; Feng SM; Strunk KE; Earp HS
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):235-46. PubMed ID: 18437540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]